Chronic Lymphocytic Leukemia
Idelalisib and Ibrutinib Continue to Advance CLL Treatment
Read More >>
View Free CME from PER >>
Venetoclax Achieves Primary Endpoint in Pivotal Phase II CLL Study
Researcher Responsible for CLL Breakthroughs Honored by ASH
Idelalisib Use Expands With New CLL Indication Pending
FDA Approval Sought for Maintenance Ofatumumab in CLL
Ibrutinib Expert Ponders Prospects for Novel Combinations in CLL
View More >>
- A Network of Your Peers
View more >>
Emerging Strategies in CLL and Follicular Lymphoma
Dr. Chanan-Khan on Ibrutinib as Backbone of Treatment for CLL
Ibrutinib-Associated Adverse Events
Ibrutinib Monotherapy and Combinations in CLL
Rituximab, Obinutuzumab, and Ofatumumab in CLL
In this segment, Myron Czuczman, MD, outlines the different roles of the various monoclonal antibodies used in the treatment of chronic lymphocytic leukemia (CLL).
Closing Thoughts: A Cure in Sight for CLL?
Panelists provide their final thoughts on CLL/NHL ad related hematology diseases.
OncLive News Network
The OncLive News Network updates viewers on breaking news, clinical trial results, FDA approvals, and offers an inside look into leading cancer centers and clinical trials.
View Now >>
2015 ASCO Annual Meeting Highlights
Laura Jones recaps major findings from the 2015 ASCO Annual Meeting, including phase III findings for new treatments in melanoma, chronic lymphocytic leukemia, lung cancer, breast cancer, and multiple myeloma.
Most Popular Right Now
American Journal of Managed Care
Oncology Nursing News
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
Terms & Conditions
666 Plainsboro Road
Plainsboro, NJ 08536
Copyright OncLive 2006-2015
Intellisphere, LLC. All Rights Reserved.